secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001193125-23-083653
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Frequency Therapeutics receives Nasdaq deficiency notice for bid price below $1; CDO departs in RIF
--------------------------------------------------------------------------------

- Nasdaq notified FREQ on March 28, 2023 that bid price closed below $1.00 for 30 consecutive business days.
- Company has until September 25, 2023 to regain compliance by closing at $1.00+ for 10 consecutive days.
- Chief Development Officer Carl LeBel terminated effective March 31, 2023 as part of reduction in force.
- LeBel receives 12 months base salary severance, COBRA payments, and $200,783 bonus (100% of 2023 bonus).
- Reduction in force follows unfavorable FX322 readout, as stated in separation agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523083653/0001193125-23-083653-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312523083653/d491154d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-083653

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer